Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women

  title={Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women},
  author={Cristiano Maria Francucci and Donato Pantaleo and Nicoletta Iori and Andrea Camilletti and F. Massi and Marco Boscaro},
  journal={Journal of Endocrinological Investigation},
The aim of our prospective, randomised, controlled and open-label clinical study was to evaluate in healthy post-menopausal women the effects of raloxifene (RLX) on body fat distribution and lipids, and the correlations between these parameters. The fat distribution, by dual energy X-ray absorptiometry, and lipids were evaluated at baseline and after 1 yr in 50 postmenopausal women: 25 were treated with RLX 60 mg/die, while 25 served as control group (CG). After 1 yr, we observed in RLX-users a… 
Oxidative stress, body fat composition, and endocrine status in pre- and postmenopausal women
It is demonstrated that fat content increases in the upper part of the body (trunk and arms) in postmenopause and that age is the main determinant of this increase.
Effect of Raloxifene on Serum Lipids for Type 2 Diabetic Menopausal Women with or without Statin Treatment
The administration of raloxifene to type 2 diabetic women showed favorable efficacy on serum lipid profiles, particularly in patients without statin treatment.
Preventive effects of raloxifene treatment on agerelated weight loss in postmenopausal women
Raloxifene treatment was a significant independent determinant of body weight and BMI and long-term treatment with raloxIFene prevents age-related weight loss.
Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial.
Raloxifene significantly changed body composition (increased FFM; increased water content) compared with placebo in postmenopausal women in a randomized, double-blind, placebo-controlled trial involving 198 healthy women aged 70 years or older.
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer
Examination of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate versus placebo, and stratified for their usage of AI versus no AI found total body mass increased and gonadal hormone levels increased.
Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice.
HT is an effective treatment for bothersome menopausal vasomotor symptoms, genitourinary syndrome, and prevention of osteoporotic fractures and can improve bothersome symptoms, all the while conferring offset benefits such as cardiovascular risk reduction and a reduction in bone fracture risk.
Raloxifene inhibits adipose tissue inflammation and adipogenesis through Wnt regulation in ovariectomized rats and 3 T3-L1 cells
A rationale for the therapeutic potential of RAL for postmenopausal obesity is provided, which may result from upregulation of secreted frizzle-related protein 5 (SFRP5), an adipokine that repressed Wnt5a signaling.
An old friend in a new light: the role of osteocalcin in energy metabolism.
Existing animal evidence regarding the role of OC and its subfractions in bone and energy metabolism and current clinical trial evidence relating to the significance and consequences of this relationship in humans are summarized.
Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management
The effects of diabetes treatment on bone metabolism, as well as the effect of antiosteoporotic medications on the incidence and control of T2D, are discussed to provide a personalized guide to the optimal management.
The Therapeutic Intervention of Sex Steroid Hormones for Sarcopenia
Sarcopenia, characterized by the excessive loss of skeletal muscle mass, strength, and function, is associated with the overall poor muscle performance status of the elderly, and occurs more


Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.
The results of this study show that raloxifene at a dose of 60 mg/d reduces serum concentrations of low-density lipoprotein cholesterol and total cholesterol in healthy older women and may have a favorable effect on the incidence of cardiovascular disease in older women.
Body weight, fat distribution and the menopausal status in women. The VMH Collaborative Group.
  • R. Pasquali, F. Casimirri, L. Barbara
  • Medicine
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1994
Investigating whether menopause may alter body weight and fat distribution in women found that body mass index was significantly higher in peri- menopausal than in pre-menopausal women and remained slightly, but again significantly, higher in post-menopause women.
The effect of raloxifene on glyco-insulinemic homeostasis in healthy postmenopausal women: a randomized placebo-controlled study.
The present data indicate that raloxifene does not negatively influence glyco-insulinemic metabolism in unselected postmenopausal women and may indeed improve the excessive insulin responsiveness to OGTT in a selected population of hyperins insulinemic post menopause women.
Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study
Continuous combined HRT was associated with decreases in total cholesterol and LDL cholesterol about twice as large as with raloxifene, but also with a decrease in HDL cholesterol, which may have important implications for the reduction of cardiovascular disease.
Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women.
The effects of raloxifene 60 mg/d on bone turnover, BMD, and serum lipids in healthy postmenopausal Asian women were similar to that previously reported in Caucasian women.
Effect of menopausal status on body composition and abdominal fat distribution
Examination of radiologic imaging techniques suggests that early-postmenopausal status is associated with a preferential increase in intra-abdominal fat that is independent of age and total body fat mass.
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides.
Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women.
The present data show that in osteopenic postmenopausal women raloxifene reduces LDL levels but does not modify insulin sensitivity and glucose metabolism.
Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.
It is demonstrated that RLX does not significantly affect glycemic control and has favorable or neutral effects on selected surrogate markers of cardiovascular risk in postmenopausal women with type 2 diabetes mellitus while decreasing hyperandrogenicity in these patients.